KarX-EC: Clinical Trials

12 trials of KarX-EC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 2 completed. 9 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 39Recruiting 9
Phase 13Completed 2, Recruiting 1

Follow KarX-EC: new trials by email Literature Review of KarX-EC trials Research Report on KarX-EC

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder
Phase 3RecruitingBristol-Myers Squibb1762026-10-062026-11-10
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder
Phase 3RecruitingBristol-Myers Squibb1762026-10-062026-11-10
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability
Phase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb company4002026-04-072026-11-06
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo - Alzheimer Disease, Psychosis
Phase 3RecruitingBristol-Myers Squibb3252026-03-252026-06-30
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
KarXT, KarX-EC - Alzheimer Disease, Agitation
Phase 3RecruitingBristol-Myers Squibb6502025-12-022026-11-12
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT, KarX-EC, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb5862025-07-212026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb4262025-07-162026-11-03
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT, KarX-EC, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb5862025-07-142026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer Disease
Phase 3RecruitingBristol-Myers Squibb4262025-07-102026-11-06
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Trospium Chloride - Healthy Volunteers
Phase 1RecruitingBristol-Myers Squibb2362025-06-272026-08-17
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
KarXT, KarX-EC - Psychiatric Disorders
Phase 1CompletedBristol-Myers Squibb242025-04-292025-08-06
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants
KarXT, KarX-EC, Placebo - Healthy Volunteers
Phase 1CompletedKaruna Therapeutics, Inc., a Bristol Myers Squibb company782024-10-012025-07-04

Conditions studied

Alzheimer Disease (6)  ·  Dementia (3)  ·  Autism Spectrum Disorder (2)  ·  Cognitive Dysfunction (2)  ·  Psychomotor Agitation (2)  ·  Autistic Disorder (1)  ·  Mental Disorders (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia (1)

Sponsors

Bristol-Myers Squibb (10)  ·  Karuna Therapeutics, Inc., a Bristol Myers Squibb company (2)

Countries

United States (11)  ·  Canada (6)  ·  France (6)  ·  Japan (6)  ·  Poland (6)  ·  Puerto Rico (6)  ·  Romania (6)  ·  Spain (6)  ·  Argentina (5)  ·  Australia (5)  ·  Germany (5)  ·  India (5)  ·  United Kingdom (5)  ·  Brazil (4)  ·  Greece (4)

NIH funding

2025 (6)